BHC

Bausch Health

• Dow Jones·01/27 17:22

  *Moody's Ratings Completes Review of Bausch With Caa2 Corporate Family Rating

• Dow Jones·01/27 17:22

  *Moody's Ratings: Stable Outlook Reflects Company's High Leverage With Generic Exposures Facing Xifaxan, Bausch's Largest Product

• Dow Jones·01/27 17:22

  *Moody's Ratings: Planning Separation of Bausch + Lomb Would Increase Business Risks

• Dow Jones·01/23 12:59

  Bausch Health Liver Disease Trials Miss Primary Endpoint

• Dow Jones·01/13 12:06

  *Bausch Health to Participate in 44th Annual J.P. Morgan Healthcare Conference Jan 14

• Dow Jones·01/13 12:06

  *Bausch Health Management Expects to Affirm Prior FY25 Guidance at Higher End of Range, Excluding Bausch + Lomb

• Dow Jones·01/07 14:38

  Bausch Health Is Maintained at Hold by Truist Securities

• Dow Jones·01/07 14:38

  Bausch Health Price Target Raised to $8.00/Share From $7.00 by Truist Securities

• Dow Jones·12/17/2025 21:32

  *Bausch + Lomb: Board Will Be Comprised of 10 Directors

• Dow Jones·12/17/2025 21:31

  *Bausch + Lomb: Eduardo C. Alfonso, MD, and Steven H. Collis Appointed to the Board

• Dow Jones·12/09/2025 15:39

  Bausch Health Initiated at Equal-Weight by Barclays

• Dow Jones·12/09/2025 15:39

  Bausch Health Price Target Announced at $8.00/Share by Barclays

• Dow Jones·12/01/2025 15:42

  Bausch Health Shares Up on Acquisition of Chinese Distribution Partner

• Dow Jones·10/30/2025 15:15

  Bausch Health Shares Climb on 3Q Profit, Revenue Rise

• Dow Jones·10/29/2025 20:14

  *Bausch Raises FY25 View To Rev $10.05B-$10.25B >BHC